Investigational agents against platinum-resistant ovarian cancer

Bibliography

• THOMAS A, MURRY T, THUN M: Cancer statistics, 2002. Cancer J. Clin. (2002) 52:23-47.
   PubMed Web of Science ®Google Scholar
• OZOLS RF: Update on management of ovarian cancer. Cancer J. (2002) 8(Suppl. 1):S22-S30.
   PubMed Web of Science ®Google Scholar
• AUZENNE E, DONATO NJ, LI C et al.: Superior therapeutic profile of poly-l-glutamic acid–paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin. Cancer Res. (2002) 8:573-581.
   PubMed Web of Science ®Google Scholar
• TODD R, SLUDDEN J, BODDY AV et al.: Phase I and pharmacological study of CT-2103, a poly (l-glutamic acid)–paclitaxel conjugate. Proc. Am. Soc. Clin. Oncol. (2001) 20(Part 1).
   Google Scholar
• SABBATINI P, BROWN J, AGHAJANIAN C et al.: A Phase I/II study of PG-paclitaxel (CT-2103) in patients with recurrent ovarian, fallopian tube, or peritoneal cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:1.
   Web of Science ®Google Scholar
• VERRILL MW, BODDY AV, TODD R et al.: Phase I pharmacokinetic study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2003):533 (Abstract).
   Google Scholar
• SHIPLEY D, GRECO A, JONES S et al.: Phase I study of CT-2103 in patients with non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2003).
   Google Scholar
• SABBATINI P, AGHAJANIAN C, DIZON D et al.: Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J. Clin. Oncol. (2004) 22:4523-4531.
   PubMed Web of Science ®Google Scholar
• CAPONIGRO F, WILLEMSE P, SORIO R et al.: A Phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer. Invest. New Drugs (2005) 23(1):85-89.
   PubMed Web of Science ®Google Scholar
• VAN KESTEREN C, CVITKOVIC E, TAAMMA A et al.: Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a Phase I dose-finding study. Clin. Cancer Res. (2000) 6:4725-4732.
   PubMed Web of Science ®Google Scholar
• BARRERA H, MOORE R, JIMENO J, VONHOFF D, FAIRCLOTH G, WEITMAN S: Interaction of ET-743 (YONDELIS™) and standard cytotoxic agents against a panel of human tumour cell lines. AACR Proceedings (1999):3896 (Abstract).
   Google Scholar
• KRASNER CN, MCMEEKIN S, CHAN S et al.: A Phase II study of weekly trabectedin (ET-743) in second/third line ovarian carcinoma. ASCO, New Orleans, USA (2004):5045 (Abstract).
   Google Scholar
• SESSA C, DE BRAUD F, PEROTTI A et al.: Trabectedin (ET-743) for women with ovarian carcinoma after of platinum-taxanes. J. Clin. Oncol. (2005) 23(9):1867-1874.
   PubMed Web of Science ®Google Scholar
• DAMIA G, SILVESTRI S, CARRASSA L et al.: Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int. J. Cancer (2001) 92:583-588.
   PubMed Web of Science ®Google Scholar
• REID JM, KUFFEL MJ, SQUILLACE DP, AMES M: Characterization of the in vitro metabolism, pharmacokinetics, and billary excretion of ecteinascidin 743 (NSC 648766) in male and female rats. Ann. Oncol. (1998):2.
   Google Scholar
• PRATT DS, KAPLAN MM: Evaluation of abnormal liver-enzyme results in asymptomatic patients. N. Engl. J. Med. (2000) 342(17):1266.
   PubMed Web of Science ®Google Scholar
• TOWNSEND DM, SHEN H, STAROS AL, GATE L, TEW KD: Efficacy of a glutathione S-transferase PI-activated prodrug in platinum-resistant ovarian cancer cells. Mol. Cancer Ther. (2002) 1(12):1089-1095.
   PubMed Web of Science ®Google Scholar
• KAVANAGH JJ, GERSHENSON DM, CHOI H et al.: Multi-institutional Phase II study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int. J. Gynecol. Cancer (2005) 15(4):593-600.
   PubMed Web of Science ®Google Scholar
• ROTH E, ZHOU S, SAMBUCETTI LC, KECK JG, XU H: TLK286, a novel glutathione analog pro-drug that induces irreversible G2/M cell cycle arrest and apoptosis in vitro in human lung, ovarian and colon cancer. Proc. Am. Assoc. Cancer Res. (2005).
   Google Scholar
• WANG Z, KECK JG, BROWN GL, XU H: TLK286, a novel glutathione analog pro-drug, induces resensitization to carboplatin in human ovarian cancer, OVCAR3, platinum resistant cells. Proc. Am. Assoc. Cancer Res. (2005).
   Google Scholar
• BERNACKI RJ, PERA P, GAMBACORTA P, BRUN Y, GRECO WR: In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs. Ann. NY Acad. Sci. (2002) 922:293-297.
   Web of Science ®Google Scholar
• VERSCHRAEGEN CF, GUPTA E, LOYER E et al.: A Phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drugs (1999) 10(4):375-383.
   PubMed Web of Science ®Google Scholar
• KERBRAT P, MONFARDINI S, VAN DER BURG M et al.: Open label Phase II study on RFS 2000 (9-nitro-camptothecin) administered orally as a 5-day on-2-day off schedule in patients with advanced ovarian cancer. Proc. Am. Assoc. Cancer Res. (2004).
   Google Scholar
• ALVERO AB, O’MALLEY D, BROWN D et al.: Molecular mechanism of phenoxodiol-induced apoptosis. Phenoxodiol, a novel approach for the treatment of ovarian cancer. Curr. Opin. Investig. Drugs (2006) 7(6):542-548.
   PubMed Web of Science ®Google Scholar
• MOR G, CHEN W, SAPI E, MALLEY D, GARG M, RUTHERFORD T: Phenoxodiol a chemosensitizer in taxotere-resistant ovarian cancer cells. Proc. Am. Assoc. Cancer Res. (2004).
   Google Scholar
• LARKIN JM, KAYE SB: Epothilones in the treatment of cancer. Expert Opin. Investig. Drugs (2006) 15(6):691-702.
   PubMed Web of Science ®Google Scholar
• ROWINSKY EK: The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann. Rev. Med. (1997) 48:353-374.
   PubMed Web of Science ®Google Scholar
• MANI S, MCDAID H, HAMILTON A et al.: Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin. Cancer Res. (2004) 10(4):1289-1298.
   PubMed Web of Science ®Google Scholar
• MONZO M, ROSELL R, SANCHEZ JJ et al.: Paclitaxel resistance in non-small cell lung cancer associated with β-tubulin gene mutations. J. Clin. Oncol. (1999) 17:1786-1793.
   PubMed Web of Science ®Google Scholar
• ROSE PG: Gencitabine reverses platinum resistance in platinum resistant ovarian and peritoneal carcinoma. Int. J. Gyn. Cancer (2005) 15:18-22.
   PubMed Web of Science ®Google Scholar
• GERONI C, MARCHINI S, COZZI P et al.: Brostallicin a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res. (2002) 62:2332-233
   PubMed Web of Science ®Google Scholar
• FERLINI C, RASPAGLIO G, MOZZETTI S et al.: The seco-taxane IDN5390 is able to target class III β-tubulin and to overcome paclitaxel resistance. Cancer Res. (2005) 5:2397-2405
   Google Scholar
• BAST RC Jr, MILLS GB: General keynote: molecular therapeutics and pharmacogenomic. Gynecol. Oncol. (2003) 88:84-87.
   Google Scholar
• SAWYERS CL, HOCHHAUS A, FELDMAN E et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a Phase II study. Blood (2002) 99:3530.
   PubMed Web of Science ®Google Scholar
• PEREZ-SOLER R, CHACHOUA A, HUBERMAN M: A Phase II trial of OSI 774 following platinum-based chemotherapy in patients with advanced, EGFR-expressing non small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2001) 19:310.
   Google Scholar
• AUERSPERG N, WONG AS, CHOI KC, KANG SK, LEUNG PC: Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. (2001) 22:255-288.
   PubMed Web of Science ®Google Scholar
• KOHLER M, JANZ I, WINTZER HO, WAGNER E, BAUKNECHT T: The expression of EGF receptors, EGF like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res. (1989) 9:1537-1547.
   PubMed Web of Science ®Google Scholar
• BRADER K, WOLF J, CHAKRABARTY S, PRICE JE: Epidermal growth factor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line. Oncol. Rep. (1998) 5:1269-1274.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F, TORTORA G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. (2001) 7:2958-2970.
   PubMed Web of Science ®Google Scholar
• BERCHUCK A, RODRIGUEZ GC, KAMEL A et al.: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am. J. Obstet. Gynecol. (1991) 164:669-674.
   PubMed Web of Science ®Google Scholar
• NICHOLSON RI, GEE JM, HARPER ME: EGFR and cancer prognosis. Eur. J. Cancer (2001) 37:9-15.
   PubMed Web of Science ®Google Scholar
• SEWELL JM, MACLEOD KG, RITCHIE A, SMYTH JF, LANGDON SP: Targeting the EGF receptor in ovarian cancer with the tyrosine-kinase inhibitor ZD 1839 (‘Iressa’). Br. J. Cancer (2002) 86:456-462.
   PubMed Web of Science ®Google Scholar
• VAN DAM PA, VERGOTE IB, LOWE DG et al..: Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J. Clin. Pathol. (1994) 47:914-919.
   PubMed Web of Science ®Google Scholar
• BOOKMAN MA, DARCY KM, CLARKE-PEARSON D, BOOTHBY RA, HOROWITZ IR: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with over-expression of HER2: a Phase II trial of the Gynecological Oncology Group. J. Clin. Oncol. (2003) 21:283-290.
   PubMed Web of Science ®Google Scholar
• MEDEN H, MARX D, ROEGGLEN T, SCHAUER A, KUHN W: Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int. J. Gynecol. Pathol. (1998) 17:61-65.
   PubMed Web of Science ®Google Scholar
• RUSSELL JS, MICHAEL WS, XIAOWEI C et al.: Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecological Oncology Group Study. Clin. Cancer Res. (2005) 11:5539-5548.
   PubMed Web of Science ®Google Scholar
• GORDON AN, FINKLER N, EDWARDS RP et al.: Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine-kinase inhibitor, in patients with advanced ovarian carcinoma: results from a Phase II multicenter study. Int. J. Gynecol. Cancer (2005) 15(5):785-792.
   PubMed Web of Science ®Google Scholar
• BRANDVOLD KA, NEIMAN P, RUDDELL A: Angiogenesis is an early event in the generation of myc-induced lymphomas. Oncogene (2000) 19:2780-2785.
   PubMed Web of Science ®Google Scholar
• GERBER HP, DIXIT V, FERRARA N: VEGF induces expression of the anti-apoptotic proteins BCL-2 and A1 in vascular endothelial cells. J. Biol. Chem. (1998) 273:13313-13316.
   PubMed Web of Science ®Google Scholar
• FERRARA N, GERBER HP, LECOURTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9(6):669-676.
   PubMed Web of Science ®Google Scholar
• HOLASH J, DAVIS S, PAPADOPOLOS N et al.: VEGF Trap: a VEGF blocker with potent anti-tumor effects. Proc. Natl. Acad. Sci. USA (2002) 99:11393-11398.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350:2335-2342.
   PubMed Web of Science ®Google Scholar
• BRUSTMANN H, NAUDE S: Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynecol. Oncol. (2002) 84(1):47-52.
   PubMed Web of Science ®Google Scholar
• SHEN GH, GHAZIZADEH M, KAWANAMI O et al.: Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br. J. Cancer (2000) 83(2):196-203.
   PubMed Web of Science ®Google Scholar
• CHEN CA, CHENG WF, LEE CN et al.: Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol. Oncol. (1999) 74(2):235-240.
   PubMed Web of Science ®Google Scholar
• BYRNE AT, ROSS L, HOLASH J et al.: Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. (2003) 9:5721-5728.
   PubMed Web of Science ®Google Scholar
• MONK BJ, HAN E, JOSEPHS-COWAN CA, PUGMIRE G, BURGER RA: Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. (2006) 102(2):140-144.
   PubMed Web of Science ®Google Scholar
• CANNISTRA SA, MATULONIS U, PENSON R: Bevacizumab in patients with advanced platinum-resistant ovarian cancer. Proc. Am. Soc. Clin. Oncol. (2006):5006 (Abstract).
   Google Scholar
• DABROW MB, FRANCESCO MR, MCBREARTY FX, CARADONNA S: The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol. Oncol. (1998) 71:29-37.
   PubMed Web of Science ®Google Scholar
• GOETZL E, BANDA M, LEPPERT D: Matrix metalloproteinases in immunity. J. Immunol. (1996) 156:1-4.
   PubMed Web of Science ®Google Scholar
• BROWN PD, GIAVAZZI R: Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann. Oncol. (1995) 6:967-974.
   PubMed Web of Science ®Google Scholar
• DE CLERCK YA, SHIMADA H, TAYLOR SM, LANGLEY KE: Matrix metalloproteinases and their inhibitors in tumor progression. Ann. NY Acad. Sci. (1994) 732:222-232.
   PubMed Web of Science ®Google Scholar
• HEATH EI, O’REILLY S, HUMPHREY R et al.: Phase I trial of the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. (2001) 48:269-274.
   PubMed Web of Science ®Google Scholar
• HIRTE H, VERGOTE IB, JEFFREY JR et al.: A Phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol. (2006) 102:300-308
   PubMed Web of Science ®Google Scholar
• MCPHILLIPS F, MULLEN P, MONIA BP et al.: Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br. J. Cancer (2001) 85:1753-1758.
   PubMed Web of Science ®Google Scholar
• OZA AM, ELIT L, SWENERTON K et al.: Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecol. Oncol. (2003) 89:129-133.
   PubMed Web of Science ®Google Scholar
• ADAMS J, PALOMBELLA VJ, SAUSVILLE EA et al.: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. (1999) 59(11):2615-2622.
   PubMed Web of Science ®Google Scholar
• CUSACK JC: Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat. Rev. (2003) 29(Suppl. 1):21-31.
   PubMed Web of Science ®Google Scholar
• AGHAJANIAN C, DIZON DS, SABBATINI P, RAIZER JJ, DUPONT J, SPRINGGS DR: Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J. Clin. Oncol. (2005) 23(25):5943-5949.
   PubMed Web of Science ®Google Scholar